DermTech (NASDAQ:DMTK) and Anpac Bio-Medical Science (NASDAQ:ANPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Valuation and Earnings
This table compares DermTech and Anpac Bio-Medical Science’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DermTech||$3.36 million||60.52||-$19.69 million||N/A||N/A|
|Anpac Bio-Medical Science||$1.56 million||36.55||-$14.52 million||N/A||N/A|
Insider and Institutional Ownership
39.1% of DermTech shares are held by institutional investors. Comparatively, 0.0% of Anpac Bio-Medical Science shares are held by institutional investors. 16.5% of DermTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares DermTech and Anpac Bio-Medical Science’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anpac Bio-Medical Science||N/A||N/A||N/A|
This is a summary of current recommendations and price targets for DermTech and Anpac Bio-Medical Science, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anpac Bio-Medical Science||0||0||0||0||N/A|
DermTech presently has a consensus price target of $24.00, indicating a potential upside of 75.95%. Given DermTech’s higher possible upside, analysts plainly believe DermTech is more favorable than Anpac Bio-Medical Science.
DermTech beats Anpac Bio-Medical Science on 6 of the 9 factors compared between the two stocks.
DermTech Company Profile
DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.
Anpac Bio-Medical Science Company Profile
Anpac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.